






















Filed • Approved

 antibody  protein  small molecule

As of Mar.31, 2018

Area		Code Name Generic Name Formulation	Mechanism of Action	Indication	Stage	In-House or Licensed	Remarks
Nephrology		KRN321 Darbepoetin Alfa Injection	Long-Acting Erythropoiesis Stimulating Agent	Renal Anemia (on Dialysis)	NDA in preparation in CN	Kirin-Amgen	
				Renal Anemia	Filed in ID		
		KRN1493 Cinacalcet Hydrochloride Oral	Calcium Receptor Agonist	Secondary Hyperparathyroidism	Filed in BN	Licensed from Shire-NPS	
		ⓄKHK7580 Evocalcet Oral	Calcium Receptor Agonist	Secondary Hyperparathyroidism	Approved in JP	Licensed from Mitsubishi Tanabe Pharma	
Oncology		KW-0761 Mogamulizumab Injection	Anti-CCR4 Humanized Antibody	Cutaneous T-cell Lymphoma	Filed in US Filed in EU Filed in JP	In-House	POTELLIGENT® Additional Indication, Dosage and Administration
		Granisetron Patch	5-HT ₃ Serotonin Receptor Antagonist	Chemotherapy induced Nausea and Vomiting	Approved in MY	Licensed from Solasia Pharma	
Immunology /Allergy		ⓄKHK4563 Benralizumab Injection	Anti-IL-5 Receptor Humanized Antibody	Asthma	Approved in JP	In-House	POTELLIGENT® Jointly Developed with AstraZeneca/MedImmune NDA holder is AstraZeneca
		KHK4827 Brodalumab Injection	Anti-IL-17 Receptor A Fully Human Antibody	Psoriasis	Filed in TW Filed in TH Filed in SG Filed in MY	Kirin-Amgen	
Central Nervous System		KW-6002 Istradefylline Oral	Adenosine A _{2A} Receptor Antagonist	Parkinson's Disease	NDA in preparation in US	In-House	
Other		ⓄKRN23 Burosumab Injection	Anti-FGF23 Fully Human Antibody	X-linked Hypophosphatemia (XLH) in pediatric patients	Approved in EU	In-House	Human Antibody-Producing Technology Jointly Developed with Ultragenyx in US and EU
				X-linked Hypophosphatemia (XLH)	Filed in US		

Phase II, Phase III








Area		Code Name Generic Name Formulation	Mechanism of Action	Indication	Stage	In-House or Licensed	Remarks
Nephrology		ⓄRTA 402 Bardoxolone Methyl Oral	Antioxidant Inflammation Modulator	CKD in Patients with Type 2 Diabetes	Phase II in JP	Licensed from Reata	
		ⓄKHK7580 Evocalcet Oral	Calcium Receptor Agonist	Hypercalcemia In Patients With Parathyroid Carcinoma or Primary Hyperparathyroidism	Phase III in JP	Licensed from Mitsubishi Tanabe Pharma	
Oncology		ⓄKHK2375 Entinostat Oral	HDAC Inhibitor	Breast Cancer	Phase II in JP	Syndax	
		KW-0761 Mogamulizumab Injection	Anti-CCR4 Humanized Antibody	Adult T-cell Leukemia/Lymphoma	Phase II in US, EU and others	In-House	POTELLIGENT®
Immunology /Allergy		ⓄKHK4083 Injection	Anti-OX40 Fully Human Antibody	Ulcerative Colitis	Phase II in US, EU and others	In-House	POTELLIGENT® Human Antibody-Producing Technology
		ⓄKHK4563 Benralizumab Injection	Anti-IL-5 Receptor Humanized Antibody	Chronic Obstructive Pulmonary Disease (COPD)	Phase III in JP	In-House	POTELLIGENT® Jointly Developed with AstraZeneca/MedImmune
				Eosinophilic Chronic Rhinosinusitis (ECRS)	Phase II in JP		
		KHK4827 Brodalumab Injection	Anti-IL-17 Receptor A Fully Human Antibody	Psoriasis	Phase III in KR	Kirin-Amgen	
			Axial Spondyloarthritis (axSpA)	Phase III in JP, KR and TW			
		ⓄASKP1240 Bleselumab Injection	Anti-CD40 Fully Human Antibody	Recurrence of Focal Segmental Glomerulosclerosis (FSGS) in <i>de novo</i> kidney transplant recipients	Phase II in US	In-House	Human Antibody-Producing Technology Jointly Developed with Astellas
Central Nervous System		KW-0761 Mogamulizumab Injection	Anti-CCR4 Humanized Antibody	HTLV-1 associated myelopathy (HAM)	Phase III in JP	In-House	POTELLIGENT®
		ⓄKW-6356 Oral	Adenosine A _{2A} Receptor Antagonist	Parkinson's Disease	Phase II in JP	In-House	
Other		ⓄKRN23 Burosumab Injection	Anti-FGF23 Fully Human Antibody	X-linked Hypophosphatemia (XLH) in adult patients	Phase III in US, CA, EU, JP and KR	In-House	Human Antibody-Producing Technology Jointly Developed with Ultragenyx in US and EU
				X-linked Hypophosphatemia (XLH) in pediatric patients	Phase III in US, CA, EU, AU, JP and KR		
				Tumor Induced Osteomalacia (TIO)/Epiderma l Nevus Syndrome (ENS)	Phase II in US Phase II in JP and KR		
		AMG531 Romiplostim Injection	Thrombopoietin Receptor Agonist	Aplastic Anemia Idiopathic (Immune) Thrombocytopenic Purpura	Phase II / III in JP and KR Phase III in CN	Kirin-Amgen	


 Updated since Dec. 31, 2017 (Area, Stage, Filed, Approved, etc.)
 New Molecular Entity

Ph I

 antibody
  protein
  small molecule





As of Mar. 31, 2018

Area		Code Name Generic Name Formulation	Mechanism of Action	Indication	Stage	In-House or Licensed	Remarks
Oncology		◎KHK2455 Oral	IDO 1 Inhibitor	Solid Tumor	Phase I in US	In-House	Combination with KW-0761
		◎KHK2823 Injection	Anti-CD123 Fully Human Antibody	Cancer	Phase I in UK	In-House	POTELLIGENT [®] Human Antibody-Producing Technology
		KW-0761 Mogamulizumab Injection	Anti-CCR4 Humanized Antibody	Solid Tumor	Phase I / II in US Phase I in JP	In-House	POTELLIGENT [®] Combination with Nivolumab (Jointly Developed with Bristol-Myers Squibb) Combination with Nivolumab (Jointly Developed with Ono Pharmaceutical)
Immunology y/Allergy		◎KHK4083 Injection	Anti-OX40 Fully Human Antibody	Ulcerative Colitis Atopic Dermatitis	Phase I in JP Phase I in JP	In-House	POTELLIGENT [®] Human Antibody-Producing Technology
		KHK4827 Brodalumab Injection	Anti-IL-17 Receptor A Fully Human Antibody	Autoimmune Disease	Phase I in JP	Kirin-Amgen	
Central Nervous System		◎KHK6640 Injection	Anti-Amyloid Beta Peptide Antibody	Alzheimer's Disease	Phase I in EU Phase I in JP	Licensed from Immunas Pharma	
Others		KW-3357 Antithrombin Gamma Injection	Recombinant Human Antithrombin	Disseminated Intravascular Coagulation, Congenital Antithrombin Deficiency	Phase I in EU	In-House	


 Updated since Dec. 31, 2017 (Area, Stage, Filed, Approved, etc.)
 ◎ New Molecular Entity

Updated since Dec. 31, 2017 (Area, Stage, Filed, Approved, etc.)

Filed • Approved

Area		Code Name Generic Name Formulation	Mechanism of Action	Indication	Stage	In-House or Licensed	Remarks
Nephrology		◎KHK7580 Evocalcet Oral	Calcium Receptor Agonist	Secondary Hyperparathyroidism	Approved in JP	Licensed from Mitsubishi Tanabe Pharma	
Oncology		Granisetron Patch	5-HT ₃ Serotonin Receptor Antagonist	Chemotherapy induced Nausea and Vomiting	Approved in MY	Licensed from Solasia Pharma	
Immunology /Allergy		◎KHK4563 Benralizumab Injection	Anti-IL-5 Receptor Humanized Antibody	Asthma	Approved in JP	In-House	POTELLIGENT [®] Jointly Developed with AstraZeneca/MedImmune NDA holder is AstraZeneca
Other		◎KRN23 Burosumab Injection	Anti-FGF23 Fully Human Antibody	X-linked Hypophosphatemia (XLH) in pediatric patients	Approved in EU	In-House	Human Antibody-Producing Technology Jointly Developed with Ultragenyx in US and EU

Terminated

Area		Code Name Generic Name Formulation	Mechanism of Action	Indication	Stage	In-House or Licensed	Remarks
Oncology		KW-0761 Mogamulizumab Injection	Anti-CCR4 Humanized Antibody	Solid Tumor	Phase I in US	In-House	POTELLIGENT [®] Combination with Durvalumab/Tremelimumab (Jointly Developed with AstraZeneca) Combination with Docetaxel Combination with PF-05082566 (Jointly Developed with Pfizer)